ClinicalTrials.gg

Smoking Cessation clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,582 studies for Smoking Cessation across more than 10 countries. 198 are recruiting or about to start. 928 of them are mainly about Smoking Cessation (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 2,117 studies for Smoking Cessation. How that becomes 1,581 here

This page counts the studies the registry files under Smoking Cessation, and those it files under no condition that list Smoking Cessationthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,117Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2List Smoking Cessation as a condition, but the registry did not file them under itMost often written as “Smartphone App-based Smoking Cessation” (1) and “Smoking Cessation Financial Incentives” (1). The registry filed them under other conditions only, most often Cigarette Smoking (1) and Tobacco Use Cessation (1).
  3. −534Match it another way397 name it in the title, 10 in a keyword, and 127 by a synonym or other text the search reads.
  4. 1,581The count on this page12 of them list Smoking Cessation in their own words; the registry filed them under no condition.

Status

Completed
1,118
Recruiting
137
Status unknown
107
Terminated
67
Active, not recruiting
50
Not yet recruiting
48

Phase

Phase 2
182
Phase 4
146
Phase 3
127
Phase 1
91
Early Phase 1
18

Where

United States
920
Canada
78
Hong Kong
59
China
51
France
48
United Kingdom
46

Who develops what

Add Smoking Cessation to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Nicotine Chewing GumRecent, limitedPhase 4 trial recorded
Evidence
  • NCT06554873 · Rose Research Center, LLC · Phase 3 · background · “Nicorette 4Mg Chewing Gum” · registered Aug 2024
  • NCT06088862 · Rose Research Center, LLC · Phase 3 · background · “Nicorette 4Mg Chewing Gum” · registered Oct 2023
Johnson & Johnson57% of its industry studies12 studies
Nicotine LozengeRecent, limited
Evidence
  • NCT06554873 · Rose Research Center, LLC · Phase 3 · background · “Nicorette Lozenge Product” · registered Aug 2024
  • NCT06088862 · Rose Research Center, LLC · Phase 3 · background · “Nicorette Lozenge Product” · registered Oct 2023
Philip Morris International100% of its industry studies12 studies
Nicotine PatchEarlier onlyPhase 4 trial recorded
Evidence
  • NCT03178422 · Chrono Therapeutics, Inc. · Phase 2 · comparator · “NicoDerm CQ Patch” · registered Apr 2017
  • NCT01655082 · Pierre Fabre · Phase 2 · comparator · “Nicotine transdermal patch” · registered Jul 2012
Johnson & Johnson45% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Oct 2027 est.Nicotine Mint Oro Dispersible Tablet (Nic ODT) · McNeil AB · Phase 2 main aimNCT07893158 A Study of Nicotine Orodispersible Tablet on Craving Relief of Male and Female Smoker Volunteers — primary endpoint: Visual Analog Scale (VAS) score change · 280 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Smoking Cessation studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 2 open · Opioid antagonists 2 open · Serotonin receptor agonists 1 open · MAO inhibitors (MAOIs) 3

Coming up

94studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger. 6 (4%) take children under 18. 8 (6%) are for women only and 1 (1%) for men only; 41 (30%) take healthy volunteers.

Recruiting studies that take each age, of 137
AgeWomenMen
103 (2%)3 (2%)
18113 (82%)106 (77%)
30121 (88%)114 (83%)
40121 (88%)114 (83%)
50126 (92%)121 (88%)
65122 (89%)117 (85%)
75105 (77%)99 (72%)
8597 (71%)91 (66%)

Across all 1,582 studies, recruiting or not: 35% stop at 75 or younger and 27% at 65; 8% take children; 6% are for women only and 2% for men only; 47% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Smoking Cessation studies take

Of 56 phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 117 mo2–34 · 34 studies——
Phase 235 mo14–60 · 51 studies—41 mo17–61 · 42 studies
Phase 329 mo16–60 · 31 studies——
Phase 435 mo21–55 · 56 studies—35 mo24–55 · 53 studies
Interventional, no phase24 mo12–44 · 564 studies—24 mo12–45 · 547 studies
Observational31 mo17–90 · 47 studies—31 mo17–90 · 42 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,582. Browse all 1,582 → or search them.